All In Biotech

Drug Trial Radar · NCT00427388

Steroids In caRdiac Surgery Trial (SIRS Trial)

Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass

Last checked: Nov 19, 2026Latest source record: Aug 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 7,507 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

7,507

Actual

Start

Jun 2007

Primary completion

Feb 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR)
First posted
Jan 29, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SIRS trial is a large simple study in which high-risk patients undergoing cardiac surgery requiring the use of cardiopulmonary bypass (CPB) are randomly allocated to receive a pulse dose of Methylprednisolone or a matching placebo. Cardiopulmonary bypass initiates a systemic inflammatory response that facilitates development of post-operative complications. SIRS will confirm or deny the potential clinical benefits of suppressing this response through the use of systemic steroids. Specifically, does 250 mg of intravenous Methylprednisolone given twice, once on anesthetic induction and again on CPB initiation, result in improved early survival and less myocardial infarction in high-risk cardiac surgery patients requiring CPB?

Conditions

  • Cardiac Surgical Procedures
  • Cardiopulmonary Bypass
  • Systemic Inflammatory Response Syndrome

Interventions

  • MethylprednisoloneDrug

    Given by IV in 2 doses (250 mg each dose for a total of 500 mg)

  • PlaceboOther

    Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality at 30 daysTime frame: 30 days post-randomization
  2. CompositeTime frame: 30 days post-randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.